Q1 2025 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2025-05-14 · accession 0001104659-25-048527
$521.8M
Reported value
13
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $134.0M | 25.7% | 4,896,462 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $118.4M | 22.7% | 2,384,456 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $95.5M | 18.3% | 9,130,465 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $51.0M | 9.77% | 6,430,257 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics, Inc. | $38.6M | 7.41% | 3,694,020 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio, Inc. | $36.1M | 6.92% | 10,402,286 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $19.8M | 3.79% | 1,137,149 | Common | SOLE |
| 92673K108 | VIGL | Vigil Neuroscience, Inc. | $10.4M | 1.99% | 5,836,874 | Common | SOLE |
| 45175G108 | — | Ikena Oncology, Inc. | $6.4M | 1.23% | 5,018,178 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $4.5M | 0.87% | 1,799,232 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio, Inc. | $3.5M | 0.66% | 2,092,106 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $3.4M | 0.64% | 8,279,484 | Common | SOLE |
| 84833T103 | SPRO | Spero Therapeutics, Inc. | $219,784 | 0.04% | 305,255 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.